APA (7th ed.) Citation

HJ, A., TM, C., J, S., D, W., K, B., L, K., . . . B, D. (2025). Efficacy and safety of guselkumab in patients with active lupus nephritis: Results from a phase 2, randomized, placebo-controlled study. Rheumatology (Oxford, England), 64(5), 2731. https://doi.org/10.1093/rheumatology/keae647

Chicago Style (17th ed.) Citation

HJ, Anders, et al. "Efficacy and Safety of Guselkumab in Patients with Active Lupus Nephritis: Results from a Phase 2, Randomized, Placebo-controlled Study." Rheumatology (Oxford, England) 64, no. 5 (2025): 2731. https://doi.org/10.1093/rheumatology/keae647.

MLA (9th ed.) Citation

HJ, Anders, et al. "Efficacy and Safety of Guselkumab in Patients with Active Lupus Nephritis: Results from a Phase 2, Randomized, Placebo-controlled Study." Rheumatology (Oxford, England), vol. 64, no. 5, 2025, p. 2731, https://doi.org/10.1093/rheumatology/keae647.